Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Multiple drugs

Type IV hypersensitivity reaction, vitiligo-like depigmentation and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Fahmy LM, et al. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatology Online Journal. 29: No. 6, Jan 2023. Available from: URL: https://dx.doi.org/10.5070/D329662993 Fahmy LM, et al. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatology Online Journal. 29: No. 6, Jan 2023. Available from: URL: https://​dx.​doi.​org/​10.​5070/​D329662993
Metadaten
Titel
Multiple drugs
Type IV hypersensitivity reaction, vitiligo-like depigmentation and lack of efficacy
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55293-y

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Crizotinib

Case report

Pembrolizumab

Case report

Aspirin